Company intelligence
Nyxoah
Make Sleep Simple
About Nyxoah
Nyxoah is reinventing sleep for the billion people that suffer from obstructive sleep apnea (OSA). We are a medical technology company that develops breakthrough treatment alternatives for OSA through neuromodulation. Our first innovation is Genio®, a battery-free hypoglossal neuromodulation device that is inserted through a single incision under the chin and controlled by a wearable. Through our commitment to innovation and clinical evidence, we have shown best-in-class outcomes for reducing OSA burden.
Verified activity
Signals from Nyxoah
22 published signals
Research & Knowledge
Nyxoah announced that Rolando Molina MD and Edward Mezerhane, MD, FAASM, FACP, DABOM, CPI for the first patient enrollment and implant in the BREATHE Study.
Reported by Scott Holstine
Research & Knowledge
Nyxoah enrolled and implanted the first patient in the BREATHE Study, a clinical trial focused on increasing HGNS clinical evidence and advancing sleep medicine.
Reported by Nyxoah
Presence & Recognition
Nyxoah expanded its training class of territory managers, marketing professionals, and field engineers across the U.S.
Reported by Nyxoah
People
Nyxoah welcomed new territory managers, marketing professionals, and field engineers to the team.
Reported by Nyxoah
Partnerships
Nyxoah partnered with Dr. Plawecki and Genio and Bilateral HGNS to help many more patients get relief from their OSA.
Reported by Doug Heidrich
Partnerships
Nyxoah brought Genio and Bilateral HGNS to the market to help patients with OSA.
Reported by Doug Heidrich
Research & Knowledge
Nyxoah published a U.S. pivotal study in patients with Complete Concentric Collapse (CCC) showing 77.2% AHI responder rate and 87.7% ODI responder rate with zero device-related serious adverse events over a 12-month period.
Reported by Nyxoah
Presence & Recognition
Nyxoah will present the complete 12-month dataset of the ACCCESS study at the International Surgical Sleep Society annual meeting in Los Angeles from October 15-16.
Reported by Nyxoah
Legal & Regulatory
Nyxoah is submitting a PMA supplement to the FDA under Breakthrough Device Designation to expand Genio's U.S. indication to Complete Concentric Collapse patients.
Reported by Nyxoah
Products & Services
Nyxoah launched the GENIO implant system in the US commercial launch in Michigan.
Reported by Scott Holstine
Presence & Recognition
Nyxoah team completed the first Genio case in Suffolk County for St. Charles Hospital.
Reported by Cynthia Palombo
Products & Services
Nyxoah announced that another state joined the Genio® community, with Dr. Mark D'Agostino completing his first Genio® procedure in Connecticut.
Reported by Nyxoah
Products & Services
Nyxoah launched the commercial first implants of the recently FDA approved GENIO in Orlando.
Reported by Scott Holstine
Presence & Recognition
Nyxoah employee Dr. Kiran Tipirneni completed his first Genio implants in Orlando.
Reported by Don Cleaver
Presence & Recognition
Nyxoah is attending the 23rd IFOS Istanbul 2026 World Congress of Otorhinolaryngology in Istanbul from 9 to 13 September.
Reported by Nyxoah
Products & Services
Nyxoah launched the first commercial GENIO implant in Brooklyn, USA, at NYU Langone Hospital.
Reported by Scott Holstine
Customers & Market
Nyxoah helped over 500 patients in one year.
Reported by Don Cleaver
Presence & Recognition
Nyxoah physician Dr. Nicolas Katsantonis, MD, FACS performed the first Genio® procedure in the state of North Carolina.
Reported by Nyxoah
Partnerships
Nyxoah partnered with Dr. Katsantonis to bring Bilateral HGNS to the North Carolina market.
Reported by Doug Heidrich
Products & Services
Nyxoah launched the first commercial implants of GENIO at the University of Colorado Anschutz for the DREAM trial.
Reported by Scott Holstine
People
Nyxoah welcomed Cynthia Palombo as part of its first Sales Advisory Council.
Reported by Cynthia Palombo
Products & Services
Nyxoah launched the first US Commercial implant of the recently FDA Approved GENIO at Yale School of Medicine.
Reported by Scott Holstine